Marina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel

NEW YORK, Feb. 28, 2017 /PRNewswire/ -- KCSA Strategic Communications, a leading New York-based communications firm, announced today that it has been selected to lead the investor relations program for Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer.

KCSA intends to deploy an investor relations campaign designed to increase awareness of Marina Biotech among the investment community through a comprehensive communications strategy. KCSA's objectives include, among others, communications, strategy and introductions to the retail and institutional investment community. Since KCSA's inception nearly fifty years ago, the firm has developed a strong reputation for its work representing public companies.

Joseph W. Ramelli, CEO of Marina Biotech, stated, "We are excited to work with KCSA in order to build greater awareness of Marina Biotech with the investment community.  With a new and focused management team in place, we believe the Company is positioned to effectively tap into the significant development and partnership opportunities available through our pipeline of innovative therapeutics.  Marina Biotech offers investors an exciting opportunity to participate in the biotech sector, addressing the disease intersections of arthritis, hypertension and cancer through the use of combination therapies."

Todd Fromer, Managing Partner of KCSA Strategic Communications, commented, "With an extensive history of counseling  public companies, including healthcare, pharmaceutical and biotechnology companies, on their engagement of the investment community, we have developed a network of micro- and small cap investors that are looking for significant value and growth opportunities such as Marina Biotech. We look forward to working with Joe and the rest of the management team in order to drive greater investor awareness of the near-term and long-term opportunities for the Company to generate shareholder value."

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and energy. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit www.kcsa.com.

About Marina Biotech
Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 -- next generation celecoxib -- which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com.

Marina Biotech Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to successfully integrate its business operations with those of IthenaPharma; (ii) the ability of Marina Biotech to obtain funding to support its clinical development; (iii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iv) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (v) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (vi) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

SOURCE KCSA Strategic Communications

Related Links

http://www.kcsa.com